SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001839882-23-009537
Filing Date
2023-04-13
Accepted
2023-04-13 16:52:40
Documents
8

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT admp-defm14a_051523.htm DEFM14A 4145073
2 GRAPHIC admppre14a001.jpg GRAPHIC 8244
3 GRAPHIC admppre14a002.jpg GRAPHIC 4451
4 GRAPHIC admppre14a003.jpg GRAPHIC 564
5 GRAPHIC admppre14a004.jpg GRAPHIC 662
6 GRAPHIC admppre14a005.jpg GRAPHIC 645
7 GRAPHIC admppre14a006.jpg GRAPHIC 63363
8 GRAPHIC admppre14a007.jpg GRAPHIC 825982
  Complete submission text file 0001839882-23-009537.txt   5391165
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-36242 | Film No.: 23818956
SIC: 2834 Pharmaceutical Preparations